Valuation: Alaunos Therapeutics, Inc.

Market Cap 4.65M 4.09M 3.8M 3.49M 6.55M 450M 6.67M 45.44M 17.72M 220M 17.46M 17.08M 762M P/E 2024
-0.65x
P/E 2025 -1.47x
Enterprise Value 3.27M 2.87M 2.67M 2.45M 4.6M 316M 4.68M 31.91M 12.44M 154M 12.26M 11.99M 535M EV / Sales 2024
195,938,500x
EV / Sales 2025 1,164,761,400x
Free-Float
85.49%
Yield 2024 *
-
Yield 2025 -
1 day+0.78%
1 week-6.32%
Current month-15.02%
1 month-10.67%
3 months-30.42%
6 months-34.45%
Current year-40.54%
1 week 1.85
Extreme 1.85
2.19
1 month 1.85
Extreme 1.85
2.48
Current year 1.85
Extreme 1.85
4.04
1 year 1.67
Extreme 1.67
4.59
3 years 1.31
Extreme 1.3137
72.75
5 years 1.31
Extreme 1.3137
601.5
10 years 1.31
Extreme 1.3137
1,182
Manager TitleAgeSince
Chief Executive Officer 63 01/07/2025
Director of Finance/CFO 41 21/02/2025
Director TitleAgeSince
Director/Board Member 57 15/12/2020
Chairman 63 21/09/2023
Director/Board Member 72 04/02/2021
Date Insider Type Main position Quantity % Market Cap.
30/06/26 Free

Chief Executive Officer

3,880 0.1589%
12/06/26 Free

Chief Executive Officer

7,761 0.3178%
22/05/26 Free

Chief Executive Officer

3,700 0.1556%
Change 5-day change 1-year change 3-year change Capi.($)
+0.03%-6.32%-35.49%-97.22% 4.65M
-1.92%-1.57%+48.70%+84.37% 55.92B
+0.93%+6.97%+62.83%+67.97% 56.67B
-2.16%-1.62%-21.45%-15.91% 23.28B
-0.62%-1.70%+2.86%+420.43% 23.28B
-0.36%-0.56%+36.00%-3.93% 20.54B
-1.34%+0.51%+25.02%-30.27% 17.78B
-1.44%-1.63%+37.07%+589.93% 15.9B
-1.30%-9.92%+160.67%+284.37% 14.64B
+0.12%-0.55%+24.17%+179.61% 13.99B
Average -0.73%-0.30%+34.04%+147.93% 24.2B
Weighted average by Cap. -0.79%+1.47%+42.63%+138.11%

Financials

2024 2025
Net sales 0.01 0.01 0.01 0.01 0.01 0.97 0.01 0.1 0.04 0.47 0.04 0.04 1.64 0 0 0 0 0.01 0.48 0.01 0.05 0.02 0.24 0.02 0.02 0.82
Net income -4.68M -4.12M -3.82M -3.52M -6.59M -453M -6.71M -45.72M -17.83M -221M -17.57M -17.19M -767M -4.18M -3.67M -3.41M -3.14M -5.88M -404M -5.99M -40.8M -15.91M -197M -15.68M -15.34M -684M
Net Debt -1.09M -960K -891K -820K -1.54M -106M -1.57M -10.66M -4.16M -51.53M -4.1M -4.01M -179M -1.38M -1.22M -1.13M -1.04M -1.95M -134M -1.99M -13.53M -5.28M -65.42M -5.2M -5.09M -227M
Logo Alaunos Therapeutics, Inc.
Alaunos Therapeutics, Inc. is a pre-clinical obesity and metabolic disorder and clinical-stage oncology-focused cell therapy company. The Company focuses on developing small molecules that are expected to be efficacious against obesity and other metabolic disorders. The Company is engaged in developing novel small molecule-based obesity therapeutics. The Company’s operations consist primarily of conducting research and development and raising capital to fund those efforts. The Company has not generated any revenues.
Employees
1
Date Price Change Volume
24/07/26 US$1.921 +0.03% 1,837
23/07/26 US$1.920 -1.54% 7,756
22/07/26 US$1.950 -6.70% 10,000
21/07/26 US$2.090 +2.96% 30,195
20/07/26 US$2.030 -0.98% 5,232

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. TCRT Stock